ImetelChat

(IMO) JNJ/Janssen still has an eye on Imetelstat. Dr. Rizo and others that spent time at Janssen are not at Geron by accident. Imetelstat has had many medical successes, with combination potential yet to be explored.

Very interesting -------The wording from the EMA for OD status needs to be compared with the FDA wording. Is it possible that OD status from the EMA, from a practical point of view, implies much more than the FDA wording. Does the EMA OD status imply that the next step or approval will soon follow (...

Kara---I don't know what you are talking about. The original MF Mayo Clinic pilot trail showed a number of remissions. Imetelstat provides these uniquely. Now we are talking about MOS (Mean Overall Survival), and that data looks very good, in some very sick patients. One definitely can live without ...

JNJ has told us that Imetelstat is a top pipeline oncology medicine, with extensive trials and unheard of remissions. The FDA has fast-tracked the medicine at JNJ's request. This is all very positive.

The Safety Profile continues to be good at all levels. Imetelstat is effective (ET, MF, MDS) and shows promise in combinations (AML & beyond). JNJ has enough data now for full approvals, in addition to the already granted ODD status (FDA & EMA). This is an unique medicine that is needed by patients ...